title: [Clinical analysis of 53 cases of esthesioneuroblastoma].
abstract: OBJECTIVE
  The prognosis of esthesioneuroblastoma (ENB) patients is poor. This study was to analyze prognostic factors and explore a rational treatment for ENB.
  
  
  METHODS
  Clinical data of 53 ENB patients, treated at Sun Yat-sen University Cancer Center from 1980 to 2003, were analyzed retrospectively. The correlation of prognostic factors to clinical features and treatment approaches were analyzed using the Kaplan-Meier method. Efficacy of different treatment modalities was compared.
  
  
  RESULTS
  The five-year overall survival (OS) was 41% of all ENB patients. The five-year OS of the surgery group, radiotherapy group, chemotherapy group, surgery combined with radiotherapy and (or) chemotherapy group, chemoradiotherapy were 42%, 38%, 0, 56%, 0, respectively, which were statistically significant (p<0.05). The five-year OS of Kadish stage A, B, C patients were 100%, 37%, 31%, respectively, which were statistically significant among these three subgroups which (p<0.05). The recurrence rate over the entire period was 51%. The five-year OS of the recurrence group and recurrence-free group were 42% and 48%, respectively, without significant differences (p>0.05).
  
  
  CONCLUSIONS
  ENB is a malignant tumor with high rates of locoregional recurrence and distant metastasis. Surgery-based multimodality is a relatively reasonable method. The prognosis of ENB is associated with the clinical stage and treatment modalities.
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, P. R. China.
authors.forename: Yan-Feng
authors.initials: YF
authors.lastname: Chen
authors.forename: An-Kui
authors.initials: AK
authors.lastname: Yang
authors.forename: Quan
authors.initials: Q
authors.lastname: Zhang
authors.forename: Dian
authors.initials: D
authors.lastname: Ouyang
authors.forename: Wen-Kuan
authors.initials: WK
authors.lastname: Chen
authors.forename: Fu-Jin
authors.initials: FJ
authors.lastname: Chen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D018304:Esthesioneuroblastoma, Olfactory / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009296:Nasal Cavity; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009669:Nose Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D011882:Radiotherapy, High-Energy; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult